Have questions or comments? Click here.
Last week the Food and Drug Administration (FDA) listened to presentations and comments from several members of an expert FDA advisory committee regarding the benefit-to-risk ratio of Long Acting Beta-agonist drugs (LABAs). The advisory panel consisted of 27 voting health care professionals representing subcommittees in pulmonary and allergy medicine, safety and risk, and pediatric advisory.
The medications of interest were LABAs prescribed for treatment... Read morePrimatene Mist, a stalwart of over the counter asthma inhalers, is heading toward oblivion in a few short weeks. A few years ago, Congress... Read more »
Asthma treatment is all about control. Control is the main goal of asthma treatment, as outlined in both the U.S. asthma management... Read more »
So it's 6 a.m. and I'm driving down I-75 South in Georgia in the wee hours of the morning when the anxiety strikes. I couldn't find my... Read more »
Chances are if you have asthma you have some degree of chronic (it's always there) inflammation in your air passages. Studies have... Read more »
In a previous post I described for you the 31 signs you are overusing your (bronchodilator) rescue inhaler. In this post I would like to... Read more »
Chronic sinusitis--a frustrating and painful disorder that affects up to 14 percent of Americans--may be eased with a steroid nasal wash, a small... Read more »
GlaxoSmithKline's new Advair HFA inhaler is now available nationwide. The inhaler offers the same corticosteroid and bronchodilator as the Advair... Read more »
This is a study to compare the safety and effectiveness of a new combination inhaler with the drugs Flonase and Foradil. This national study is... Read more »
Most people who experience “sciatica” are really experiencing the shooting, searing sensation of neurogenic pain (pain coming from a nerve) as... Read more »
Experts say there are some concerns that adding steroids to long-acting beta agonists may do more harm than good for COPD patients. A new study... Read more »